Prestwick Pharmaceuticals Overview

  • Founded
  • 2002
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 29
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $100M
Latest Deal Amount

Prestwick Pharmaceuticals General Information

Description

Developer of small molecule drugs for chronic diseases of the central nervous system (CNS). The company focuses on restless legs syndrome, schizophrenia, autism, Alzheimer's and sleep apnea ailments.

Contact Information

Formerly Known As
KCS Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 1825 K Street Northwest
  • Suite 1475
  • Washington, DC 20006
  • United States
+1 (202) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Prestwick Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 17-Sep-2008 $100M 00000 00000 Completed Clinical Trials - Phase 3
7. Debt - General 02-Aug-2007 00000 00000 Completed Clinical Trials - Phase 3
6. Later Stage VC (Series C1) 13-Apr-2007 000.00 00000 00000 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series C) 23-Aug-2006 000.00 000.00 00000 Completed Startup
4. IPO 20-Dec-2005 000.00 Cancelled Clinical Trials - Phase 3
3. Early Stage VC (Series B) 01-Dec-2004 0000 000.00 000.00 Completed Startup
2. Early Stage VC (Series A2) 19-Jun-2003 $13M $23.1M 000.00 Completed Startup
1. Early Stage VC (Series A) 10-Mar-2003 $10.1M $10.1M 000.00 Completed Startup
To view Prestwick Pharmaceuticals’s complete valuation and funding history, request access »

Prestwick Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C2 00,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series C1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A2 13,030,570 $0.001000 8% $1 $1 1x $1 13.88%
Series A1 10,065,999 $0.001000 8% $1 $1 1x $1 10.73%
To view Prestwick Pharmaceuticals’s complete cap table history, request access »

Prestwick Pharmaceuticals Patents

Prestwick Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-2445888-A 4,4-dimethylpiperidine-2, 6-dione derivatives for use in the treatment of hypertension Granted 14-Sep-2005 0000000000
GB-0807094-D0 4,4-dimethylpiperidine-2, 6-dione derivatives for use in the treatment of hypertension Granted 14-Sep-2005 0000000000
GB-2445888-B Treatment of hypertension Expired - Fee Related 14-Sep-2005 0000000000
GB-0518763-D0 Treatment of hypertension Ceased 14-Sep-2005 0000000000
US-7514454-B2 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate; serotonin receptor antagonist; antidepressant, anxiolytic agent; migraine and sleep apnoea; weight loss and hepatocyte changes Expired - Fee Related 22-Aug-2002 C07D211/88 0

Prestwick Pharmaceuticals Executive Team (7)

Name Title Board Seat Contact Info
William Washecka Chief Financial Officer
Arthur Mandell Executive Vice President
Robert Raide Executive Vice President & Chief Business Officer
Christopher O'Brien MD Chief Medical Officer & Senior Vice President
Melvin Booth Executive Chairman
You’re viewing 5 of 7 executive team members. Get the full list »

Prestwick Pharmaceuticals Board Members (3)

Name Representing Role Since
Melvin Booth Prestwick Pharmaceuticals Executive Chairman 000 0000
You’re viewing 1 of 3 board members. Get the full list »

Prestwick Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prestwick Pharmaceuticals Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Atlas Venture Venture Capital Minority 000 0000 000000 0
CNF Investments PE/Buyout Minority 000 0000 000000 0
Pequot Ventures Venture Capital Minority 000 0000 000000 0
Scale Venture Partners Venture Capital Minority 000 0000 000000 0
Sofinnova Investments Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »